Xubin Li

ORCID: 0000-0003-1727-9215
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • CAR-T cell therapy research
  • Lymphoma Diagnosis and Treatment
  • Immune Cell Function and Interaction
  • Cancer Immunotherapy and Biomarkers
  • T-cell and B-cell Immunology
  • Single-cell and spatial transcriptomics
  • Viral Infectious Diseases and Gene Expression in Insects
  • Genomics and Chromatin Dynamics
  • Cancer Mechanisms and Therapy
  • Chromatin Remodeling and Cancer
  • Biosimilars and Bioanalytical Methods
  • Virus-based gene therapy research
  • Integrated Circuits and Semiconductor Failure Analysis

The University of Texas MD Anderson Cancer Center
2022-2024

SMARCA4 encodes one of two mutually exclusive ATPase subunits in the BRG/BRM associated factor (BAF) complex that is recruited by transcription factors (TFs) to drive chromatin accessibility and transcriptional activation. among most recurrently mutated genes human cancer, including ∼30% germinal center (GC)-derived Burkitt lymphomas. In mice, GC-specific Smarca4 haploinsufficiency cooperated with MYC over-expression lymphomagenesis. Furthermore, monoallelic deletion drove GC hyperplasia...

10.1016/j.ccell.2024.02.011 article EN cc-by-nc-nd Cancer Cell 2024-03-07

Autologous anti-CD19 chimeric antigen receptor T cell (CAR T) therapy is highly effective in relapsed/refractory large B lymphoma (rrLBCL) but associated with toxicities that delay recovery. While the biological mechanisms of cytokine release syndrome and neurotoxicity have been investigated, pathophysiology poorly understood for prolonged cytopenia, defined as grade ≥3 cytopenia lasting beyond 30 days after CAR infusion. We performed single-cell RNA sequencing bone marrow samples from...

10.1016/j.xcrm.2023.101158 article EN cc-by-nc-nd Cell Reports Medicine 2023-08-01

Abstract Multiple therapies with immune mechanisms of action such as CAR T-cells and bispecific antibodies are now approved for relapsed/refractory large B-cell lymphoma (rrLBCL). The efficacy these is likely influenced by microenvironment (LME) characteristics, but have not been directly characterized in a comprehensive fashion. We therefore performed single-nucleus multiome (RNA + ATAC), bulk RNA, WES 119 biopsies from 114 patients to capture both hematopoietic non-hematopoietic cell...

10.1158/2643-3249.lymphoma24-pr06 article EN Blood Cancer Discovery 2024-06-19

<div>Abstract<p>Follicular lymphoma (FL) is a B-cell malignancy with complex tumor microenvironment that rich in nonmalignant immune cells. We applied single-cell RNA sequencing to characterize the diverse and cell populations of FL identified major phenotypic subsets T cells, including cytotoxic CD4 T-cell population. characterized four subtypes differential representation or relative depletion distinct subsets. By integrating exome sequencing, we observed somatic mutations are...

10.1158/2643-3230.c.6550995 preprint EN 2023-04-04

<div>Abstract<p>Follicular lymphoma (FL) is a B-cell malignancy with complex tumor microenvironment that rich in nonmalignant immune cells. We applied single-cell RNA sequencing to characterize the diverse and cell populations of FL identified major phenotypic subsets T cells, including cytotoxic CD4 T-cell population. characterized four subtypes differential representation or relative depletion distinct subsets. By integrating exome sequencing, we observed somatic mutations are...

10.1158/2643-3230.c.6550995.v1 preprint EN 2023-04-04

SUMMARY Chimeric antigen receptor (CAR) T-cell therapy has been a breakthrough for relapsed or refractory large B-cell lymphoma (rrLBCL). However, suboptimal CAR activity can lead to therapeutic failure and dismal outcome. Using single cell RNA-sequencing of rrLBCL tumors, we identify prominent population clonally expanded dysfunctional CAR+ CD8 T-cells indicative ongoing tumor engagement, proliferation, dysfunction at the time progression from therapy. Furthermore, show that patient-derived...

10.1101/2023.08.28.555127 preprint EN cc-by-nc-nd bioRxiv (Cold Spring Harbor Laboratory) 2023-08-29
Coming Soon ...